Therapeutic area
  • Animal health

What the technology does

The Entry-component Replication-Abortive (ECRA) vaccine strain of the African Horse Sickness Virus (AHSV) is genetically engineered to stimulate an immune response in the host animal, but not replicate and cause infection.


ECRA AHSV vaccination with multiple serotypes is possible, giving a clear advance over existing vaccines. It does not need inactivating or cold storage for administration in the field. ECRA ECRA AHSV enters the cell normally (without the use of an adjuvant), but cannot complete a full replication cycle. The vaccine causes production of sufficient protein to elicit an immune response. ECRA AHSV can be produced at biosafety level 2, lowering production costs, and the viral titre is maintained following
dessication, enabling delivery / administration in the field in the absence of refrigeration. Horse trials using ECRA AHSV cocktails against multiple serotypes have been successfully conducted.

Main application field



This opportunity is available for licencing and co-development.

All Licensing Opportunities